Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

Investigational New Drugs

Volumn 25, Issue 6, 2007, Pages 565-570

  Beer, Tomasz M ^a,j   Higano, Celestia S ^b   Saleh, Mansoor ^c   Dreicer, Robert ^d   Hudes, Gary ^e   Picus, Joel ^f   Rarick, Mark ^g   Fehrenbacher, Louis ^h   Hannah, Alison L ⁱ  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Georgia Cancer Specialists   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g KAISER PERMANENTE   (United States)

^h KAISER PERMANENTE MEDICAL CENTER   (United States)

ⁱ KOSAN BIOSCIENCES INC   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Docetaxel; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DESOXYEPOTHILONE B; DOCETAXEL; EPOTHILONE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TAXOID; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 39549088960     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-007-9068-1     Document Type: Article

References (14)

1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756-1764 (Pubitemid 26185452)
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502-1512 (Pubitemid 39315317)
3. Chou TC, O'Connor OA, Tong WP, Guan Y, Zhang ZG, Stachel SJ, Lee C, Danishefsky SJ (2001) The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci U S A 98(14):8113-8118 (Pubitemid 32642695)
4. Chou TC, Zhang XG, Harris CR, Kuduk SD, Balog A, Savin KA, Bertino JR, Danishefsky SJ (1998) Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A 95(26):15798-15802 (Pubitemid 29018780)
5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17(11):3461-3467 (Pubitemid 29517916)
6. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98(8):516-521 (Pubitemid 43898814)
7. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1-10
8. Buzdar A, Silverman P, Kaufmann P, Waintraub S, Doyle T, Kroener J, Robinson P, Zhang A, DeMario M (2005) A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. San Antonio Breast Cancer Symposium Proceedings: abstract 1087
9. Yee L, Lynch T, Villalona-Calero M, Rizvi N, Gabrail N, Sandler A, Cropp G, Palmer G (2005) A Phase II Study of KOS-862 (Epothilone D) as Second-Line Therapy in Non-Small Cell Lung Cancer. Proceedings of the American Society for Clinical Oncology: abstract 7127
10. Petrylak DP, Sartor O, Witjes F, Ferrero J, Berry WR, Koletsky A, Falcon S, Nathan FE, Petrone ME, Sternberg C (2007) A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Prostate Cancer Symposium Proceedings: 144
11. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23(7):1439-1446
12. Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED (2005) Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23(34):8724 - 8729
13. Lin AM, Rosenberg JE, Weinber VK, Kelly WK, Michaelson MD, Hussain M, Wilding G, Gross ME, Small E (2006) Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP). J Clin Oncol 24(18S):231s
14. Hussain A, Dipaola RS, Baron AD, Higano CS, Tchekmediyan NS, Miller JA, Rothermel JD (2004) A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). J Clin Oncol 22(14S):397s